Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 17/20 | 0.69 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.51 |
| ▸ | AKT2 | P31751 | 2/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13997805 | 0.88 | RPS6KA5 (0.66) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4595603 | 0.88 | RPS6KA5 (0.66) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4596048 | 0.87 | RPS6KA5 (0.65) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4596386 | 0.85 | GSK3B (0.67) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL13997806 | 0.85 | RPS6KA5 (0.62) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4595203 | 0.85 | RPS6KA5 (0.62) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL14008313 | 0.84 | AKT1 (0.58) | RPS6KA5GSK3BAKT1AKT2AKT3 | |
| SCHEMBL4718900 | 0.81 | RPS6KA5 (1.00) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4596346 | 0.81 | RPS6KA5 (0.60) | RPS6KA5ROCK1GSK3BRPS6KB1PRKACA | |
| SCHEMBL4595168 | 0.80 | AKT1 (0.78) | GSK3BAKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885ROCK1 478/4885GSK3B 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.